 Hello, my name is Karen Keating. I'm Senior Director, Global Health Economics, Outcomes and Reimbursement in the Market Axis Department, Ecology Strategic Business Unit at Bayer Pharmaceuticals in Wibony, New Jersey, in the United States. I've been with Bayer for almost 30 years. I'm involved in three CISAQUAL IMI work packages. Work package three, the feasibility of developing recommendations for non-RCTs, including single-arm studies, work package four, communication of PRO findings, and work package eight, patient engagement, dissemination strategies, and educational programs and workshops. My role in CISAQUAL IMI will be to provide insights from the perspective of a PRO researcher at Bayer with over 15 years experience in oncology. Key expected outcomes from our perspective in the industry setting are that patients will ultimately benefit from better understanding of endpoints that are highly relevant to them and will become better equipped for shared decision-making, that there will be better guidelines for the design, analysis, and interpretation of health-related quality of life and PRO findings from cancer clinical trials. This will support the regulatory approval and reimbursement of drugs, such as by track eight, neurotrack tip. These benefits will be included in ratings of drug benefits by ESMO and ASCO in their value scales, and representatives from health technology assessment organizations, as well as payers, will incorporate PRO data more readily into their decision-making.